SEL-302
/ Cartesian Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 24, 2024
reiMMAgine: A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Selecta Biosciences, Inc. | Suspended ➔ Withdrawn
Trial withdrawal • Genetic Disorders • Metabolic Disorders • Ophthalmology • Pediatrics
May 08, 2023
reiMMAgine: A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
(clinicaltrials.gov)
- P1/2 | N=6 | Suspended | Sponsor: Selecta Biosciences, Inc. | Recruiting ➔ Suspended
Trial suspension • Genetic Disorders • Immune Modulation • Metabolic Disorders • Ophthalmology • Pediatrics
March 21, 2023
reiMMAgine: Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
(clinicaltrials.gov)
- P1/2 | N=6 | Recruiting | Sponsor: Selecta Biosciences, Inc.
New P1/2 trial • Genetic Disorders • Immune Modulation • Metabolic Disorders • Ophthalmology • Pediatrics
1 to 3
Of
3
Go to page
1